Suppr超能文献

在晚期心力衰竭中增加螺内酯:每天剂量大于 25 毫克对血浆钾浓度的影响。

Increased Spironolactone in Advanced Heart Failure: Effect of Doses Greater than 25 mg/Day on Plasma Potassium Concentration.

出版信息

Cardiorenal Med. 2013 Apr;3(1):1-6. doi: 10.1159/000346447. Epub 2013 Jan 30.

Abstract

BACKGROUND

Daily doses of spironolactone higher than 25 mg are rarely used in heart failure (HF) patients, presumably due to the concern for hyperkalemia. However, in advanced HF, doses ≥50 mg have been found to be necessary to produce natriuresis. The aim of the present study was to examine the safety of natriuretic doses of spironolactone (50-200 mg) on serum potassium concentration in New York Heart Association (NYHA) class III/IV HF patients over several weeks.

METHODS

18 patients with advanced HF received 50-200 mg of spironolactone in addition to standard treatment. Serum electrolytes, BUN and serum creatinine were assessed at baseline, during increased doses of spironolactone and at the 1-month follow-up.

RESULTS

During a total of 738 patient-weeks, there was no significant increase in mean serum potassium (4.0 vs. 4.2 mEq/l) or serum creatinine (1.3 vs. 1.4 mg/dl). However, in 3 patients, spironolactone treatment was stopped due to a mean increase in serum creatinine (1.9 vs. 2.6 mg/dl) and in one of them, an increase in serum potassium (4.4 vs. 5.2 mEq/l) was noted.

CONCLUSION

Increased doses of spironolactone are generally safe during outpatient follow-up in selected patients with advanced HF, who are receiving treatment with ACE inhibitors, beta-blockers, and loop diuretics.

摘要

背景

心力衰竭(HF)患者很少使用高于 25 毫克的螺内酯日剂量,大概是因为担心高钾血症。然而,在晚期 HF 中,发现需要≥50 毫克的剂量才能产生利钠作用。本研究的目的是在数周内检查大剂量螺内酯(50-200 毫克)对纽约心脏协会(NYHA)III/IV 级 HF 患者血清钾浓度的安全性。

方法

18 名晚期 HF 患者在标准治疗的基础上加用 50-200 毫克螺内酯。在基线、增加螺内酯剂量期间和 1 个月随访时评估血清电解质、BUN 和血清肌酐。

结果

在总共 738 个患者周期间,平均血清钾(4.0 与 4.2 mEq/l)或血清肌酐(1.3 与 1.4 mg/dl)无显著增加。然而,在 3 名患者中,由于血清肌酐平均增加(1.9 与 2.6 mg/dl)和其中 1 名患者的血清钾增加(4.4 与 5.2 mEq/l),停止了螺内酯治疗。

结论

在接受 ACE 抑制剂、β受体阻滞剂和袢利尿剂治疗的选择晚期 HF 患者门诊随访期间,增加螺内酯剂量通常是安全的。

相似文献

3
Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
Am J Cardiol. 2012 Mar 1;109(5):693-8. doi: 10.1016/j.amjcard.2011.10.027. Epub 2011 Dec 5.
5
Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
Eur J Intern Med. 2011 Aug;22(4):424-7. doi: 10.1016/j.ejim.2011.04.008. Epub 2011 May 31.
7
Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
Am Heart J. 2004 Dec;148(6):971-8. doi: 10.1016/j.ahj.2004.10.005.
9
Safety of spironolactone use in ambulatory heart failure patients.
Clin Cardiol. 2008 Nov;31(11):509-13. doi: 10.1002/clc.20284.

引用本文的文献

1
2
Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure.
JACC Heart Fail. 2016 Sep;4(9):726-35. doi: 10.1016/j.jchf.2016.06.003. Epub 2016 Aug 10.
3
Mineralocorticoid Receptor Antagonism in Acute Heart Failure.
Curr Treat Options Cardiovasc Med. 2015 Sep;17(9):402. doi: 10.1007/s11936-015-0402-1.
4
Treatment Approaches to Congestion Relief in Acute Decompensated HF: Insights After DOSE-AHF and CARRESS-HF.
Curr Treat Options Cardiovasc Med. 2014 Aug;16(8):330. doi: 10.1007/s11936-014-0330-5.
5
Decongestion in acute heart failure.
Eur J Heart Fail. 2014 May;16(5):471-82. doi: 10.1002/ejhf.74. Epub 2014 Mar 5.
6
Role of diuretics and ultrafiltration in congestive heart failure.
Pharmaceuticals (Basel). 2013 Jul 4;6(7):851-66. doi: 10.3390/ph6070851.
7
Cardiorenal syndrome: pathophysiology and treatment.
Curr Cardiol Rep. 2013 Jul;15(7):380. doi: 10.1007/s11886-013-0380-4.

本文引用的文献

1
Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival.
Circulation. 2010 Jul 20;122(3):265-72. doi: 10.1161/CIRCULATIONAHA.109.933275. Epub 2010 Jul 6.
2
3
Aldosterone 'escape' vs 'breakthrough'.
Nat Rev Nephrol. 2010 Feb;6(2):61. doi: 10.1038/nrneph.2009.228.
4
Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
Circ Heart Fail. 2009 Jul;2(4):370-6. doi: 10.1161/CIRCHEARTFAILURE.108.821199.
5
Renal failure in cirrhosis.
N Engl J Med. 2009 Sep 24;361(13):1279-90. doi: 10.1056/NEJMra0809139.
6
Rehospitalizations among patients in the Medicare fee-for-service program.
N Engl J Med. 2009 Apr 2;360(14):1418-28. doi: 10.1056/NEJMsa0803563.
7
Decreased effective blood volume in edematous disorders: what does this mean?
J Am Soc Nephrol. 2007 Jul;18(7):2028-31. doi: 10.1681/ASN.2006111302. Epub 2007 Jun 13.
8
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
N Engl J Med. 2004 Aug 5;351(6):543-51. doi: 10.1056/NEJMoa040135.
10
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
N Engl J Med. 2003 Apr 3;348(14):1309-21. doi: 10.1056/NEJMoa030207. Epub 2003 Mar 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验